In the decades since the HIV/AIDS epidemic first emerged as a global health crisis, the medical community has achieved what was once thought impossible: transforming a certain death sentence into a manageable chronic condition. Today, through the rigorous application of antiretroviral therapy (ART), many individuals living with HIV can achieve an "undetectable" viral load, allowing them to live long, healthy lives and effectively eliminating the risk of transmitting the virus to others. Yet, despite these monumental strides, a true cure has remained frustratingly out of reach. The virus remains a permanent resident in the human body, hiding in silence, waiting for the moment a patient stops their medication to begin its destructive replication once again.
New research from the University of Virginia School of Medicine has finally shed light on one of the most significant obstacles to a total cure. Scientists at UVA have uncovered a critical mechanism that dictates how HIV enters, maintains, and emerges from its dormant state. The study reveals that the virus’s ability to remain hidden or to reawaken is not a simple binary choice but is instead controlled by subtle genetic variations that act like a dimmer switch, or a rheostat, regulating the intensity of the virus’s activity.
These insights, led by a multidisciplinary team at UVA’s Myles H. Thaler Center for AIDS and Human Retrovirus Research, provide a new roadmap for scientists attempting to "flush out" the virus from its hiding places. By understanding the specific viral controls that allow HIV to remain stubbornly dormant, researchers are now closer to developing strategies that could eventually eliminate the virus from the body for good.
The Challenge of the Viral Reservoir
To understand the significance of the UVA discovery, one must first understand the primary hurdle in HIV research: the "latent reservoir." When a person takes antiretroviral drugs, the medication successfully prevents the virus from replicating and infecting new cells. However, HIV is an exceptionally "clever" pathogen. Early in the infection process, the virus integrates its genetic material into the DNA of the host’s immune cells, particularly CD4+ T cells.
While many of these infected cells are active and eventually destroyed, a small number of them enter a resting or "latent" state. In this mode, the virus does not produce new copies of itself. Because it is biologically "silent," it remains invisible to the immune system, which only recognizes active threats. Furthermore, because antiretroviral drugs are designed to interfere with the replication process, they have no effect on these dormant cells.
"HIV treatment is lifesaving but also lifelong," explained Patrick Jackson, MD, one of the two lead authors of the new study. "Understanding how the virus stays latent in cells could help us develop a lasting cure for HIV."
As long as these latent cells exist, the patient is never truly free of the virus. If treatment is interrupted, even after years of successful suppression, the latent virus can "re-prime" and begin a massive wave of replication, leading to a resurgence of the disease. This "stealth mode" is the reason why current treatments are a stalemate rather than a victory.
Moving Beyond the "On-Off" Switch
For years, the scientific consensus regarding HIV’s transition from dormancy to activity was relatively simple. Many researchers believed that the virus operated with a basic "on-off" switch. In this view, certain triggers would simply flip the switch, causing the virus to begin replicating.
However, the UVA team’s findings suggest a much more nuanced reality. Their research focused on a specific regulatory system within the virus known as the Rev-RRE axis. This system is composed of a viral protein called Rev and a complex RNA structure known as the Rev Response Element (RRE). For HIV to replicate, it must move its genomic RNA—the "operating instructions" for creating new viruses—from the nucleus of the host cell into the cytoplasm. The Rev-RRE axis acts as the gatekeeper for this transport process.
"Early on many scientists thought that the Rev-RRE axis was merely an on-off switch for the virus. However, our recent studies have shown that it functions more like a rheostat," said Marie-Louise Hammarskjold, MD, PhD, associate director of UVA’s Myles H. Thaler Center.
By describing the system as a rheostat, Hammarskjold and her colleagues are highlighting that the Rev-RRE axis can be set to different levels of "brightness" or activity. The study found that subtle genetic variations in this axis directly influence how efficiently the virus can export its RNA and, consequently, how quickly it can replicate.
David Rekosh, PhD, director of the Thaler Center, emphasized the direct link between this genetic variability and the clinical challenge of curing the disease. "We’ve known for some time that the Rev-RRE axis varied in activity," Rekosh said. "This study links it directly to how well the virus can replicate and re-activate from latency."
Understanding HIV’s Regulatory Machinery
The mechanics of the Rev-RRE axis are central to the virus’s survival strategy. The UVA study demonstrated that when a virus possesses a "low-activity" Rev-RRE axis, it faces a significant disadvantage in terms of replication speed. However, this apparent weakness is actually a survival advantage when it comes to evading a cure.
Viruses with lower Rev activity are more likely to enter a deep state of latency that is incredibly difficult to reverse. Because their "rheostat" is turned down so low, they do not respond easily to the signals that would normally trigger viral reactivation. This variability helps explain why, in clinical trials, some pockets of the virus are easily cleared while others remain stubbornly persistent despite the use of powerful "latency-reversing agents."
This discovery has profound implications for a popular cure strategy known as "shock and kill." In this approach, doctors use drugs to "shock" the latent virus out of hiding, forcing the infected cells to start producing viral proteins. Once the virus is active, the immune system or targeted therapies can then "kill" the cells and clear the reservoir.
The UVA research suggests that "shock and kill" has struggled in the past because it may not be powerful enough to overcome the low-activity Rev-RRE rheostat in many latent cells.
"Rev has often been overlooked in the context of latency, even though it’s essential for HIV replication. Our work helps explain why some current ‘shock and kill’ approaches struggle to fully reactivate the virus," said Godfrey Dzhivhuho, PhD, the other lead author of the study. "If a portion of the viral reservoir has low Rev-RRE activity, it will be more resistant to reactivation."
Dzhivhuho suggests that the next generation of HIV therapies may need to be "smarter." Instead of just shocking the virus, future treatments might need to specifically target and enhance the Rev-RRE axis, effectively turning the rheostat up to ensure a complete and robust reactivation. Only then can the "kill" phase of the strategy be truly effective.
A Personal Mission for a Global Problem
The scientific breakthrough at UVA is also a story of international collaboration and personal dedication. For lead author Godfrey Dzhivhuho, the quest for an HIV cure is deeply personal.
Dzhivhuho’s journey to the University of Virginia began years ago in South Africa, a nation that has been disproportionately affected by the HIV epidemic. Currently, more than 8 million people in South Africa are living with the virus. Dzhivhuho first met Rekosh and Hammarskjold when the two UVA professors were teaching summer sessions at the University of Venda.
Inspired by the potential to make a difference in his home country and beyond, Dzhivhuho pursued his PhD in HIV immunology at the University of Cape Town. He eventually joined the Thaler Center at UVA, bringing his expertise and firsthand understanding of the epidemic’s impact to the laboratory.
"Coming from South Africa, where HIV affects so many lives, I’ve always wanted to be part of the effort to end this epidemic," Dzhivhuho said. "I hope this work brings us one step closer to a cure, not just by uncovering how the virus works, but by helping design smarter strategies to finally eliminate it. That’s what drives me every day in this research."
The Path Forward
The UVA findings represent a significant shift in how researchers view the lifecycle of HIV. By moving away from the "on-off" switch model and embracing the complexity of the Rev-RRE rheostat, the scientific community can begin to develop more tailored interventions.
Future research will likely focus on finding molecular tools that can manipulate this rheostat. If scientists can learn how to artificially "turn up" the Rev-RRE activity in latent cells, they may finally be able to expose the entire viral reservoir to the immune system.
The work conducted at the University of Virginia School of Medicine was a collaborative effort supported by the Myles H. Thaler Research Support Gift and several grants from the National Institutes of Health (NIH), including grants R21 AI134208 and K08 AI136671. As these researchers continue their work, the goal remains clear: to move beyond the management of HIV and toward a definitive end to the epidemic.
The discovery of the Rev-RRE rheostat does not provide a cure overnight, but it provides something equally essential: a clearer understanding of the enemy’s defenses. In the long and difficult battle against HIV, knowing exactly how the virus hides is the first step toward making sure it has nowhere left to run.
